IMC Chicago
MLTX icon

IMC Chicago’s MoonLake Immunotherapeutics MLTX Stock Holding History

IMC Chicago’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
54,500
-14,600
-21% -$265K ﹤0.01% 3785
2026
Q1 		$1.29M Buy
69,100
+1,600
+2% +$26.5K ﹤0.01% 3017
2025
Q4 		$890K Buy
67,500
+13,100
+24% +$155K ﹤0.01% 3071
2025
Q3 		$390K Buy
+54,400
New +$2.84M ﹤0.01% 3310

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IMC Chicago's MLTX Position: Q2 2026 in Review

IMC Chicago increased its MoonLake Immunotherapeutics (MLTX) stake by 103% in Q2 2026, buying an estimated $212K and bringing the position to 23,048 shares worth $449K. The position accounts for ﹤0.01% of the portfolio, ranked #4776.

IMC Chicago first reported a position in MLTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $481K in Q4 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • IMC Chicago held 23,048 shares of MoonLake Immunotherapeutics worth $449K as of Q2 2026.
  • IMC Chicago bought 11,696 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $212K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #4776 holding.
  • IMC Chicago first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • IMC Chicago's MoonLake Immunotherapeutics position peaked at $481K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.